OncoMatch/Clinical Trials/NCT03743298
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
Is NCT03743298 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies AV-MEL-1 for metastatic melanoma.
Treatment: AV-MEL-1 — This is an open label, single-arm, phase IB treatment study to determine the safety of administering anti-PD1 monoclonal antibodies with AV-MEL-1 and to get some suggestion of efficacy, in patients with measurable metastatic melanoma. The study is open to patients who have either never received treatment for metastatic melanoma or were previously treated with anti-PD-1 with or without anti-CTLA-4 or with enzymatic inhibitors of the BRAF/MEK pathway because of BRAF600E/K mutations, and are about to initiate anti-PD-1 monotherapy. The intent is to treat 14 to 20 patients with the combination of anti-PD-1 and AV-MEL-1.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Metastatic disease required
Diagnosis of metastatic melanoma with at least one lesion that is amenable for surgical resection per standard of care
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Jericho Rabago · Irvine, California
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify